Clinical Trial Update: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older [Phase 3]

View source ↗

Summary

Phase 3 trial assessing immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine in adults 56 and older; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Infections
• Meningococcal Meningitis

Drugs mentioned

• Invest investigational quadrivalent meningococcal conjugate vaccine

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningitis, Meningococcal Meningitis | Phase 3 | Status: COMPLETED | Results posted: 2020-02-18